Clinical Trial Update: A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) [Phase 2]

View source ↗

Summary

Phase 2 study results of Brentuximab Vedotin in Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphoma have been completed. The results were posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Seagen Inc. | Conditions: Hodgkin Disease, Peripheral T Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2024-06-11